UNSPSC 51171816: Ondansetron

This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C18H19N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AF302ESOS, chemically known as 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazol-4-one but generally known as ondansetron, which bears US NIH Compound Identifier 4595. European Medicines Agency schedules Ondansetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09445MIG.

UNSPSC 51171816 Ondansetron is a Commodity code for a specific pharmaceutical product — an anti-nausea medication — that state and local health agencies, criminal justice departments, and cooperative purchasing alliances procure either as part of broader pharmaceutical supply contracts or through specialized pharmacy benefit initiatives. Recent solicitation activity shows demand primarily from county correction and supervision departments, state health and human services commissions, and multistate cooperative purchasing groups sourcing generic pharmaceuticals for distribution across state and local facilities.

State and local issuing bodies range from individual counties (Collin County Community Supervision and Corrections Department in Texas) to state health agencies (Texas Health and Human Services Commission) to multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which serves participating jurisdictions across multiple states including Oregon). Recent opportunities show a mix of specialized demand — such as Collin County's RFP for offender drug testing services posted July 9, 2026 with response due July 23, 2026 — and broad-based pharmaceutical contracting. The Texas HHS Commission issued an RFI on April 3, 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling state-level interest in alternative procurement models. MMCAP's January 20, 2026 RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, represents the largest-scale cooperative sourcing activity, requiring vendors to supply through authorized wholesalers and establish pricing across multiple states. Geographic activity concentrates in Texas and the upper Midwest (Minnesota, Oregon), with cooperative purchasing vehicles expanding reach across state boundaries and federal funding tied to state criminal justice appropriations.